GSK PLC Sponsored ADR $GSK Shares Acquired by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. raised its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 4.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 375,481 shares of the pharmaceutical company’s stock after acquiring an additional 16,999 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in GSK were worth $14,418,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in GSK. HHM Wealth Advisors LLC boosted its position in shares of GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock worth $26,000 after acquiring an additional 460 shares in the last quarter. Costello Asset Management INC acquired a new position in shares of GSK during the 1st quarter worth about $31,000. SOA Wealth Advisors LLC. boosted its position in shares of GSK by 252.1% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 605 shares in the last quarter. Richardson Financial Services Inc. boosted its position in shares of GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock worth $33,000 after acquiring an additional 472 shares in the last quarter. Finally, Olde Wealth Management LLC acquired a new position in shares of GSK during the 1st quarter worth about $36,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of GSK in a research report on Wednesday, October 8th. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. Seven investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of “Reduce” and an average target price of $37.38.

GSK Stock Up 0.6%

GSK stock opened at $44.21 on Thursday. The stock has a 50-day simple moving average of $41.31 and a 200-day simple moving average of $39.16. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. The company has a market capitalization of $89.87 billion, a P/E ratio of 20.47, a PEG ratio of 1.98 and a beta of 0.53. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $45.59.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.12 by $0.11. The firm had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The firm’s revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities research analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 9th. Shareholders of record on Friday, August 15th were issued a dividend of $0.4206 per share. This represents a $1.68 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date was Friday, August 15th. GSK’s dividend payout ratio is 78.24%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.